Cellectis SA
USUSDCellectis SA (LSE:0WA2) — Biotechnology: Pharmaceutical Preparations. Anzahl der Börsen, an denen die Aktien des Unternehmens gehandelt werden: 3. Auf dieser Seite: Kurs und Chart, Dividenden, größte Aktionäre und Entwicklung der Aktienanzahl.
Über das Unternehmen
- Website
- cellectis.com
- Investor Relations
- cellectis.com/en/investors/governance/
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hauptsitz
- France, France
- CEO
- Andre Choulika
- Mitarbeiter
- 224
- Gegründet
- 1999
- Börsennotiert Seit
- 09.01.2018 (LSE:0WA2)
- Ausstehende Aktien
- 72.72 Mio.
- Streubesitz
- 48.58 Mio.
- Marktkapitalisierung
- 148.06 Mio. USD
- Insider
- 0%
- Institutionelle Anleger
- 15.36%
- Branche (SIC)
- Biological Products, (No Diagnostic Substances)
- Rechtsform
- QVPB
- ISIN
- FR0010425595
- LEI
- 5493000KKX5VQ37Q2W83
- FCF
- −41.8 Mio. USD
- Schulden
- 0
- Gewinne und FCF – für die 12 Monate bis 31.12.2025 (aktueller Bericht des Unternehmens).
Beschreibung
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Größte Anteilseigner
| Inhaber | Anteil | Aktien | Berichtsdatum |
|---|---|---|---|
| B Group, Inc. | 4.55% | 3.28 Mio. | 2026-06-30 |
| Long Focus Capital Manag… | 3.8% | 2.74 Mio. | 2026-06-30 |
| UBS AM, a distinct busin… | 3.67% | 2.64 Mio. | 2026-06-30 |
| iShares Trust-iShares Bi… | 0.33% | 235 696 | 2026-08-31 |
| Nomura Asset Management… | 0.31% | 226 875 | 2026-06-30 |
| Delaware Group Equity Fu… | 0.31% | 226 875 | 2026-06-30 |
| Blackrock Inc. | 0.31% | 225 444 | 2026-06-30 |
| Morgan Stanley | 0.12% | 85 455 | 2026-06-30 |
| LPL Financial LLC | 0.12% | 84 415 | 2026-06-30 |
| Susquehanna Internationa… | 0.07% | 50 453 | 2026-06-30 |
| BNP Paribas Financial Ma… | 0.06% | 40 100 | 2026-06-30 |
| UBS Group AG | 0.05% | 33 926 | 2026-06-30 |
| Fidelity Concord Street… | 0% | 1 949 | 2026-07-31 |
